Setmelanotide in a Single Patient With Partial Lipodystrophy

Summary

The objective of this single patient study is to assess the safety and efficacy of setmelanotide as a treatment of severe metabolic abnormalities resulting from LD, especially refractory hypertriglyceridemia leading to recurrent bouts of pancreatitis.

Timeline

Start

2017-08-15

Primary completion

2018-01-31

Completion

2018-01-31

Drugs

Indications